News | Cath Lab | September 10, 2019

Complete Revascularization Superior to Culprit Lesion-only Intervention

Results from COMPLETE trial show significant reduction in major cardiovascular events including cardiovascular death, myocardial infarction and ischemia-driven revascularization

Complete Revascularization Superior to Culprit Lesion-only Intervention

September 10, 2019 — An international randomized trial has shown that complete revascularization reduces major cardiovascular events compared to culprit lesion-only percutaneous coronary intervention (PCI). Late breaking results of the COMPLETE trial were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, and published in the New England Journal of Medicine.[1]

Up to 50 percent of patients with ST-segment elevation myocardial infarction (STEMI) have multivessel coronary artery disease. This means that in addition to the blocked artery that caused the heart attack (known as the culprit artery), they have additional narrowed arteries (called non-culprit) supplying blood to the heart.

In STEMI patients, opening the culprit artery with PCI reduces cardiovascular death or myocardial infarction. It is unclear whether additional PCI of non-culprit lesions also prevents these events.

“The question of whether to routinely revascularize non-culprit lesions or manage them conservatively with guideline-directed medical therapy alone is a common dilemma,” said principal investigator Prof. Shamir R. Mehta of the Population Health Research Institute, McMaster University, Hamilton, Canada.

Observational studies suggest a reduction in clinical events with staged, non-culprit lesion PCI, but are limited by selection bias and confounding. Prior randomized trials found declines in composite outcomes with non-culprit lesion PCI but were not powered to detect improvements in hard, irreversible clinical outcomes such as cardiovascular death or new myocardial infarction. While meta-analyses indicate a decline in cardiovascular death or myocardial infarction with non-culprit lesion PCI, there has been no single, large trial showing benefit on this clinically important outcome. The COMPLETE trial was designed to address this evidence gap.

A total of 4,041 patients with STEMI and multivessel coronary artery disease were enrolled from 140 centers in 31 countries. Patients were randomly allocated to complete revascularization with additional PCI of angiographically significant non-culprit lesions, or to no further revascularization. Randomization was stratified by the intended timing of non-culprit lesion PCI: either during or after the index hospitalization.

The first co-primary outcome was the composite of cardiovascular death or myocardial infarction; the second co-primary outcome also included ischemia-driven revascularization.

At a median follow-up of three years, the first co-primary outcome of cardiovascular death or myocardial infarction occurred in 158 patients (7.8 percent) in the complete revascularization group compared to 213 (10.5 percent) in the culprit-lesion only group (hazard ratio [HR] 0.74; 95 percent confidence interval [CI] 0.60–0.91; p=0.004).

The second co-primary outcome of cardiovascular death, myocardial infarction or ischemia-driven revascularization occurred in 179 patients (8.9 percent) in the complete revascularization group compared to 399 (16.7 percent) in the culprit-lesion only group (HR 0.51; 95 percent CI 0.43–0.61; p<0.001).

There were no significant differences between groups in the occurrence of stroke (p=0.27) or major bleeding (p=0.15).

Regarding the timing of non-culprit lesion PCI, complete revascularization consistently reduced the first co-primary outcome in those stratified to receive non-culprit lesion PCI during the index hospitalization (HR 0.77; 95 percent CI 0.59–1.00) and after hospital discharge (HR 0.69; 95 percent CI 0.49–0.97; interaction p=0.62).

Mehta said, “COMPLETE is the first randomized trial to show that complete revascularization reduces hard cardiovascular events compared to culprit-lesion only PCI in patients with STEMI and multivessel coronary artery disease. The benefits emerged over the long term and were observed regardless of whether non-culprit lesion PCI was performed early, during the initial hospitalization or shortly after hospital discharge. These findings are likely to have a large impact on clinical practice and prevent many thousands of recurrent heart attacks globally every year.”

For more information: www.escardio.org

Reference

1. Mehta S.R., Wood D.A., Storey R.F., et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. New England Journal of Medicine, published online Sept. 1, 2019. DOI: 10.1056/NEJMoa1907775

Related Content

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp